FATE — Fate Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $132.66m
- -$82.76m
- $13.63m
- 43
- 31
- 71
- 46
Annual income statement for Fate Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 31.4 | 55.8 | 96.3 | 63.5 | 13.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 160 | 273 | 405 | 254 | 224 |
| Operating Profit | -128 | -217 | -308 | -191 | -210 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -173 | -212 | -282 | -161 | -186 |
| Net Income After Taxes | -173 | -212 | -282 | -161 | -186 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -173 | -212 | -282 | -161 | -186 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -173 | -212 | -282 | -161 | -186 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.1 | -2.24 | -2.91 | -1.64 | -1.51 |